Definition · Reviewed July 24, 2026
What does GLP-1 stand for?
The letters, the class they name, and the one drug everybody files under GLP-1 that technically isn't one.
The short answer
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after a meal. The medications people call “GLP-1s” are more precisely GLP-1 receptor agonists— drugs that switch that hormone's receptor on. You will see the same class written as GLP-1 RA, GLP-1 agonist, or the older incretin mimetic. All three mean the same thing.
Key takeaways
- GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after eating, not a brand or a drug.
- A GLP-1 receptor agonist (often shortened to GLP-1 RA, or just "GLP-1 agonist") is a drug that switches that hormone receptor on; "incretin mimetic" is an older name for the same idea.
- Semaglutide, liraglutide, dulaglutide and exenatide are true GLP-1 receptor agonists — sold as Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Trulicity, Byetta and Bydureon BCise.
- Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor co-agonist, not a pure GLP-1 — it activates a second receptor as well, which is why its trial weight loss runs higher.
- That distinction is not pedantry: plan documents are written by drug class, so "GLP-1s are excluded" and "tirzepatide is excluded" are not automatically the same sentence.
- Several class members are gone from the US market — Victoza was discontinued in April 2024, Byetta and Bydureon BCise in October 2024.
What each part of the name is doing
- Glucagon-like— the hormone's structure resembles glucagon, a different blood-sugar hormone. It is a family resemblance, not a shared job.
- Peptide — a short chain of amino acids. That is what the hormone is made of, and it is why most of these drugs are injected: peptides are digested if swallowed, which is the problem the oral versions had to engineer around.
- -1 — it was the first of its kind identified, distinguishing it from GLP-2, a related peptide with a different role in the gut.
- Receptor agonist — the drug part. An agonist binds a receptor and turns it on. So a GLP-1 receptor agonist produces the effects your own GLP-1 would, but at drug-level strength and duration.
Who is actually in the class
Semaglutide — GLP-1 receptor agonist
Brands: Ozempic, Wegovy, Rybelsus
The most widely prescribed member. Ozempic is diabetes-labeled, Wegovy weight-management, Rybelsus the daily oral tablet.
Tirzepatide — GIP/GLP-1 receptor co-agonist
Brands: Mounjaro, Zepbound
Activates the GIP receptor in addition to the GLP-1 receptor, so it is not a pure GLP-1 despite being grouped with them everywhere.
Liraglutide — GLP-1 receptor agonist (short half-life)
Brands: Saxenda, Victoza
Daily rather than weekly injection. Victoza was discontinued in the US in April 2024; Saxenda is a separate product with its own status.
Dulaglutide — GLP-1 receptor agonist (Fc-fusion)
Brands: Trulicity
Weekly auto-injector, labeled for type 2 diabetes and cardiovascular risk reduction rather than weight management.
Exenatide — GLP-1 receptor agonist (synthetic exendin-4)
Brands: Byetta, Bydureon BCise
The oldest members of the class. Both were discontinued in the US in October 2024 — commercial decisions, not safety recalls.
The distinction that costs money: tirzepatide is not a pure GLP-1
Mounjaro and Zepbound contain tirzepatide, a dual GIP/GLP-1 co-agonist. It hits a second receptor — glucose-dependent insulinotropic polypeptide — on top of the GLP-1 one, which is the mechanistic reason its trial weight loss runs higher than semaglutide's. Calling it a GLP-1 in conversation is harmless. Assuming a plan document means the same thing by the phrase is not: exclusions and formularies are written by drug class, so read the exact wording rather than the category you have in your head. If a plan says “GLP-1 receptor agonists are excluded”, whether that captures tirzepatide is a question to ask, not to assume.
Why one class has four names
You will meet the same drugs under different labels depending on who is writing:
- GLP-1 agonist — the everyday shorthand, used by clinicians and patients
- GLP-1 RA— the same thing with “receptor agonist” abbreviated; common in journals and plan documents
- Incretin mimetic — the older pharmacological term. Incretins are the gut hormones that trigger insulin after eating; these drugs mimic them
- Weight-loss injection — a consumer description, not a drug class, and the one most likely to confuse a coverage conversation
When you are on the phone with an insurer, the useful move is to name the molecule and the brand— “tirzepatide, brand name Zepbound” — rather than the class. Class words are where coverage conversations go wrong.
Compare GLP-1 providers on real monthly cost
SponsoredOnce you know which molecule you are actually asking about, prices become comparable. These are US-licensed providers ranked on what you pay — we compare and link, we never sell medication.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Sesame Care· from $208/moTop ratedTelehealth · online visit
- SkinnyRx· from $199/moCompounded not offered in AL, LA, MS — check before startingTelehealth · online visitCompounded · not FDA-approved
- Enhance MD· price shown after their intakeNo lab work to startRestricted in AL, AR, GA, HI, LA, MS, MO, ND, SC, TN, WV — check before startingTelehealth · online visitCompounded · not FDA-approved
- HealthRX· from $165/moLowest starting priceon the 12-month plan, $1,188 billed upfrontTelehealth · online visitCompounded · not FDA-approved
Common questions about GLP-1 terminology
What does GLP-1 stand for?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your intestine releases after you eat, which prompts insulin release, suppresses glucagon, slows how fast the stomach empties, and signals fullness to the brain. The medications people call "GLP-1s" are not the hormone itself — they are drugs that act on its receptor.
What does the "agonist" in GLP-1 agonist mean?
An agonist is a substance that binds a receptor and switches it on, producing the same kind of response the natural hormone would. So a GLP-1 receptor agonist is a drug that activates the GLP-1 receptor. You will see it abbreviated GLP-1 RA, shortened to "GLP-1 agonist", or written as "incretin mimetic" — an older term meaning a drug that mimics gut hormones. All three describe the same class.
Is Mounjaro or Zepbound a GLP-1?
Not a pure one. Both contain tirzepatide, which is a dual GIP/GLP-1 receptor co-agonist — it activates the glucose-dependent insulinotropic polypeptide receptor in addition to the GLP-1 receptor. In everyday conversation it is grouped with GLP-1s, and that is fine. In a formulary document written by drug class, the difference can matter, so read plan wording literally rather than assuming the categories match.
What are the different kinds of GLP-1 drugs?
By molecule: semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon BCise) are GLP-1 receptor agonists. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 co-agonist. They differ in dosing frequency — daily, weekly, or oral — in approved indication, and in how much weight loss the trials showed.
What are the other names for semaglutide?
Semaglutide is the generic molecule name. In the US it is sold as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral tablet. There is no FDA-approved generic version of the injectable pen, so any product marketed as "generic Ozempic" is either compounded or counterfeit.
Are all GLP-1 medications still available?
No. Three left the US market in 2024: Victoza (liraglutide) in April, and Byetta and Bydureon BCise (exenatide) in October. These were commercial discontinuations rather than safety recalls — the newer weekly drugs were both more effective and easier to take. Semaglutide, tirzepatide and dulaglutide products remain available.
Keep reading
Drug-class descriptions reflect the FDA-approved labeling for each product as of July 2026. Discontinuation dates are the 2024 US market announcements. General information, not medical advice.